LATISHA FLEMING: Open Payments
NPI 1205128725 · OCEAN SPRINGS, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,445 in 59 payments from 17 companies in 2025. Trend: 2023 $292 · 2024 $362 · 2025 $1,445
Food & beverage: $1,445
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $428 |
| Ipsen Biopharmaceuticals, Inc | 5 | $260 |
| Janssen Biotech, Inc. | 9 | $227 |
| Gilead Sciences, Inc. | 5 | $96 |
| Celltrion USA Inc. | 4 | $86 |
| Aimmune Therapeutics, Inc. | 3 | $64 |
| Lilly USA, LLC | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 4 | $40 |
| ORPHALAN INC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
Products named: IQIRVO, TREMFYA, RINVOQ, SKYRIZI, VEGZELMA, LINZESS, ZENPEP, OMVOH.
Industry payments across MS — which companies pay providers there.
